Atara Biotherapeutics Stock Performance
| ATRA Stock | USD 8.49 0.40 4.94% |
The firm shows a Beta (market volatility) of -0.0224, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Atara Biotherapeutics are expected to decrease at a much lower rate. During the bear market, Atara Biotherapeutics is likely to outperform the market. Atara Biotherapeutics right now shows a risk of 9.87%. Please confirm Atara Biotherapeutics semi deviation, sortino ratio, semi variance, as well as the relationship between the standard deviation and value at risk , to decide if Atara Biotherapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Atara Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Atara Biotherapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 93.1 M |
Atara |
Atara Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 1,163 in Atara Biotherapeutics on November 2, 2024 and sell it today you would lose (314.00) from holding Atara Biotherapeutics or give up 27.0% of portfolio value over 90 days. Atara Biotherapeutics is currently generating 0.0063% in daily expected returns and assumes 9.8735% risk (volatility on return distribution) over the 90 days horizon. In different words, 87% of stocks are less volatile than Atara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Atara Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atara Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Atara Biotherapeutics, and traders can use it to determine the average amount a Atara Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 6.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATRA |
Estimated Market Risk
| 9.87 actual daily | 87 87% of assets are less volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Atara Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Atara Biotherapeutics by adding Atara Biotherapeutics to a well-diversified portfolio.
Atara Biotherapeutics Fundamentals Growth
Atara Stock prices reflect investors' perceptions of the future prospects and financial health of Atara Biotherapeutics, and Atara Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Atara Stock performance.
| Return On Equity | -20.15 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.62) % | ||||
| Current Valuation | 31.61 M | ||||
| Shares Outstanding | 5.76 M | ||||
| Price To Earning | (4.50) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 0.78 X | ||||
| Revenue | 8.57 M | ||||
| EBITDA | (266 M) | ||||
| Cash And Equivalents | 331.31 M | ||||
| Cash Per Share | 3.51 X | ||||
| Total Debt | 57.87 M | ||||
| Debt To Equity | 0.29 % | ||||
| Book Value Per Share | (23.30) X | ||||
| Cash Flow From Operations | (192.98 M) | ||||
| Earnings Per Share | (25.32) X | ||||
| Total Asset | 165.5 M | ||||
| Retained Earnings | (1.97 B) | ||||
| Current Asset | 324.6 M | ||||
| Current Liabilities | 9.71 M | ||||
About Atara Biotherapeutics Performance
By analyzing Atara Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Atara Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Atara Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Atara Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Atara Biotherap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 578 people.Things to note about Atara Biotherapeutics performance evaluation
Checking the ongoing alerts about Atara Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Atara Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Atara Biotherapeutics had very high historical volatility over the last 90 days | |
| Atara Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 8.57 M. Net Loss for the year was (276.13 M) with loss before overhead, payroll, taxes, and interest of (125.96 M). | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (192.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Roughly 22.0% of the company shares are held by company insiders |
- Analyzing Atara Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Atara Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Atara Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Atara Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Atara Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Atara Biotherapeutics' stock. These opinions can provide insight into Atara Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |